×
About 64,420 results

ALLMedicine™ Pancreatic Cancer Center

Research & Reviews  30,459 results

The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synth...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914341
Theranostics Nie H, Huang PQ et. al.

Mar 5th, 2021 - Prolactin binding to the prolactin receptor exerts pleiotropic biological effects in vertebrates. The prolactin receptor (PRLR) has multiple isoforms due to alternative splicing. The biological roles and related signaling of the long isoform (PRLR...

Readily available biomarkers predict poor survival in metastatic pancreatic cancer.
https://doi.org/10.1080/1354750X.2021.1893814
Biomarkers : Biochemical Indicators of Exposure, Response... Strijker M, van Veldhuisen E et. al.

Mar 5th, 2021 - BACKGROUND: Identification of metastatic pancreatic cancer (mPC) patients with worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a nationwide cohort of mPC patients.ME...

Immunity boost against pancreatic cancer.
https://doi.org/10.1038/d41591-021-00012-w
Nature Medicine; Carmona J

Mar 4th, 2021 - Immunity boost against pancreatic cancer.|2021|Carmona J,|

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
https://doi.org/10.1007/s12094-021-02573-1 10.1016/S2468-1253(19)30347-4 10.1016/j.cell.2011.11.025 10.1038/s41575-0190109-y 10.1158/1078-0432.CCR-19-3724 10.1158/1078-0432.CCR-18-3121 10.1200/PO.19.00330 10.1126/science.aay9189 10.1002/bjs.9468 10.1245/s10434-008-9839-8 10.1093/annonc/mdx310 10.1016/S0140-6736(16)32409-6 10.1056/NEJMoa1809775 10.1200/JCO.19.02274 10.4174/astr.2018.94.4.190 10.1200/JCO.2007.15.8634 10.1200/JCO.2020.38.15_suppl.4504 10.1245/s10434-015-4649-2 10.1001/jama.2016.4324 10.1056/NEJMoa1011923 10.1056/NEJMoa1304369 10.1016/S1470-2045(13)70021-4 10.1016/S0140-6736(15)00986-1 10.1056/NEJMoa1903387 10.1126/science.aan6733 10.1016/j.ejca.2016.10.004 10.1002/14651858.CD007519.pub2 10.1016/S1542-3565(04)00055-2 10.1016/j.pan.2018.10.010 10.1016/S1470-2045(14)71123-4 10.1200/EDBK_160831 10.1158/1055-9965.EPI-17-1003 10.1016/j.jhep.2014.01.021 10.1038/nrclinonc.2017.157 10.2214/AJR.07.3599 10.1148/rg.285075183 10.1016/j.ctrv.2018.09.002 10.21037/cco.2019.07.06 10.1016/S1470-2045(18)30915-X 10.1200/JCO.2014.60.2219 10.1200/JCO.2011.40.5381 10.1056/NEJMoa0908721 10.1093/oxfordjournals.annonc.a010676 10.1200/JCO.2010.29.3605 10.1038/sj.bjc.6603648 10.1038/sj.bjc.6605779 10.1093/annonc/mdt540 10.1200/JCO.2019.37.15_suppl.4003 10.1016/S1470-2045(20)30157-1 10.1016/S1470-2045(20)30109-1 10.1200/JCO.2019.37.4_suppl.187 10.1200/JCO.19.02105 10.1093/annonc/mdz253 10.1056/NEJMoa1714448 10.1158/2159-8290.CD-16-1237
Clinical & Translational Oncology : Official Publication ... Gómez-España MA, Montes AF et. al.

Mar 4th, 2021 - Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery i...

Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO...
https://doi.org/10.1016/j.clinre.2020.101607
Clinics and Research in Hepatology and Gastroenterology; Breton C, Meyer A et. al.

Mar 4th, 2021 - This study reports the efficacy and safety of local treatment of metastases of pancreatic ductal adenocarcinoma (PDAC), with a curative intent. We retrospectively included patients with histologically proven PDAC, who underwent a local treatment f...

see more →

Guidelines  89 results

Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077959
Pancreas Okusaka T, Nakamura M et. al.

Mar 6th, 2020 - Clinical Practice Guidelines for Pancreatic Cancer were first published in 2006 by the Japan Pancreas Society, and they were revised in 2009, 2013, and 2016. In July 2019, the Clinical Practice Guidelines for Pancreatic Cancer 2019 were newly revi...

Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practic...
https://doi.org/10.1016/j.prro.2019.06.016
Practical Radiation Oncology; Palta M, Godfrey D et. al.

Sep 2nd, 2019 - This guideline systematically reviews the evidence for treatment of pancreatic cancer with radiation in the adjuvant, neoadjuvant, definitive, and palliative settings and provides recommendations on indications and technical considerations. The Am...

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recomm...
https://doi.org/10.1001/jama.2019.10232
JAMA , Owens DK et. al.

Aug 6th, 2019 - Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its ...

Screening for Pancreatic Cancer Updated Evidence Report and Systematic Review for the US Preventive Services Task Force
https://jamanetwork.com/journals/jama/fullarticle/2740726
JAMA

Aug 5th, 2019 - Importance Pancreatic adenocarcinoma is the third most common cause of cancer death among men and women in the United States. Objective To systematically review benefits and harms of screening for pancreatic adenocarcinoma to inform the US Prev...

see more →

Drugs  91 results see all →

Clinicaltrials.gov  32,357 results

The short isoform of PRLR suppresses the pentose phosphate pathway and nucleotide synth...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914341
Theranostics Nie H, Huang PQ et. al.

Mar 5th, 2021 - Prolactin binding to the prolactin receptor exerts pleiotropic biological effects in vertebrates. The prolactin receptor (PRLR) has multiple isoforms due to alternative splicing. The biological roles and related signaling of the long isoform (PRLR...

Readily available biomarkers predict poor survival in metastatic pancreatic cancer.
https://doi.org/10.1080/1354750X.2021.1893814
Biomarkers : Biochemical Indicators of Exposure, Response... Strijker M, van Veldhuisen E et. al.

Mar 5th, 2021 - BACKGROUND: Identification of metastatic pancreatic cancer (mPC) patients with worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a nationwide cohort of mPC patients.ME...

Immunity boost against pancreatic cancer.
https://doi.org/10.1038/d41591-021-00012-w
Nature Medicine; Carmona J

Mar 4th, 2021 - Immunity boost against pancreatic cancer.|2021|Carmona J,|

SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
https://doi.org/10.1007/s12094-021-02573-1 10.1016/S2468-1253(19)30347-4 10.1016/j.cell.2011.11.025 10.1038/s41575-0190109-y 10.1158/1078-0432.CCR-19-3724 10.1158/1078-0432.CCR-18-3121 10.1200/PO.19.00330 10.1126/science.aay9189 10.1002/bjs.9468 10.1245/s10434-008-9839-8 10.1093/annonc/mdx310 10.1016/S0140-6736(16)32409-6 10.1056/NEJMoa1809775 10.1200/JCO.19.02274 10.4174/astr.2018.94.4.190 10.1200/JCO.2007.15.8634 10.1200/JCO.2020.38.15_suppl.4504 10.1245/s10434-015-4649-2 10.1001/jama.2016.4324 10.1056/NEJMoa1011923 10.1056/NEJMoa1304369 10.1016/S1470-2045(13)70021-4 10.1016/S0140-6736(15)00986-1 10.1056/NEJMoa1903387 10.1126/science.aan6733 10.1016/j.ejca.2016.10.004 10.1002/14651858.CD007519.pub2 10.1016/S1542-3565(04)00055-2 10.1016/j.pan.2018.10.010 10.1016/S1470-2045(14)71123-4 10.1200/EDBK_160831 10.1158/1055-9965.EPI-17-1003 10.1016/j.jhep.2014.01.021 10.1038/nrclinonc.2017.157 10.2214/AJR.07.3599 10.1148/rg.285075183 10.1016/j.ctrv.2018.09.002 10.21037/cco.2019.07.06 10.1016/S1470-2045(18)30915-X 10.1200/JCO.2014.60.2219 10.1200/JCO.2011.40.5381 10.1056/NEJMoa0908721 10.1093/oxfordjournals.annonc.a010676 10.1200/JCO.2010.29.3605 10.1038/sj.bjc.6603648 10.1038/sj.bjc.6605779 10.1093/annonc/mdt540 10.1200/JCO.2019.37.15_suppl.4003 10.1016/S1470-2045(20)30157-1 10.1016/S1470-2045(20)30109-1 10.1200/JCO.2019.37.4_suppl.187 10.1200/JCO.19.02105 10.1093/annonc/mdz253 10.1056/NEJMoa1714448 10.1158/2159-8290.CD-16-1237
Clinical & Translational Oncology : Official Publication ... Gómez-España MA, Montes AF et. al.

Mar 4th, 2021 - Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery i...

Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO...
https://doi.org/10.1016/j.clinre.2020.101607
Clinics and Research in Hepatology and Gastroenterology; Breton C, Meyer A et. al.

Mar 4th, 2021 - This study reports the efficacy and safety of local treatment of metastases of pancreatic ductal adenocarcinoma (PDAC), with a curative intent. We retrospectively included patients with histologically proven PDAC, who underwent a local treatment f...

see more →

News  1,331 results

Pegilodecakin No Aid to FOLFOX in Metastatic Pancreatic Cancer
https://www.medscape.com/viewarticle/946610

Mar 1st, 2021 - NEW YORK (Reuters Health) - Adding immunotherapy pegylated IL-10 (pegilodecakin) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) in patients with advanced gemcitabine-refractory pancreatic cancer does not improve overall survival, according...

Cancer Death Rates Continue to Fall in Europe, Except For...
https://www.medscape.com/viewarticle/946288

Feb 22nd, 2021 - Cancer death rates overall continue to fall among both men and women in Europe, with the notable exception of pancreatic cancer in both sexes and lung cancer among women living in the European Union, notes an update report. "Among the major cancer...

High Cost of Pancreatic Enzymes a Barrier for Patients With Cancer
https://www.medscape.com/viewarticle/944683

Jan 25th, 2021 - Pancreatic enzyme replacement therapy (PERT) is often an essential component of the treatment regimen for patients with pancreatic cancer, but it can be very pricey. "Out-of-pocket costs for a 30-day supply of enzymes for Medicare beneficiaries ca...

New Standard for Borderline Resectable Pancreatic Cancer
https://www.medscape.com/viewarticle/944381

Jan 19th, 2021 - Patients with borderline resectable pancreatic cancer (PDAC) are often treated with chemotherapy, radiotherapy, or both before undergoing surgery, but the optimal regimen in this setting is controversial. New results suggest that the reference reg...

NHS England Starts Pilot Trial of Blood Test for Many Cancers
https://www.medscape.com/viewarticle/942024

Dec 3rd, 2020 - A simple blood test, claimed to detect more than 50 types of cancer, will be used in a pilot trial by National Health Service (NHS) England in a bid to increase rates of early-stage diagnosis, in particular for cancers that are currently difficult...

see more →

Patient Education  93 results see all →